Description
Olumiant (baricitinib) is a prescription medication used to treat adults with moderate to severe rheumatoid arthritis. It is an oral medication that works by inhibiting the activity of Janus kinases (JAKs), which play a role in inflammation and joint damage. Olumiant is manufactured by Eli Lilly and Company and comes in the form of 2 mg and 4 mg tablets.
Uses:
Olumiant is used to treat signs and symptoms of rheumatoid arthritis in adults who have previously tried other medications without success. It can improve joint pain and swelling, physical function, and reduce the progression of joint damage.
Storage Conditions:
Olumiant tablets should be stored at room temperature, away from heat, moisture, and light. The tablets should be kept in their original packaging until used. Patients should check the expiration date before taking the medication.
Mechanism of Action:
Olumiant is a type of medication that belongs to a class called JAK inhibitors. The medication inhibits the activity of the Janus kinases (JAKs) signaling pathway, which is involved in the inflammatory pathway. This reduction in inflammation helps to reduce joint pain, swelling, and stiffness, ultimately improving the overall function of the affected joint(s).
HOW TO USE:
Olumiant should be taken orally, once daily with or without food. Patients should take the medication at the same time every day. The tablets should be swallowed whole, without breaking, crushing, or chewing.
Precautions:
Patients should inform their healthcare provider of any allergies or medical conditions before taking Olumiant. Patients with liver disease, tuberculosis, or an infection should inform their healthcare provider before taking Olumiant. Olumiant may increase the risk of infections, so patients should avoid contact with others who are sick.
Drug Interactions:
Olumiant may interact with other medications that suppress the immune system, such as methotrexate and corticosteroids. It may also interact with medications used to treat fungal infections, such as ketoconazole and itraconazole. Patients should inform their healthcare provider of any other medications they are taking.
Contraindications:
Olumiant should not be used in patients with severe liver disease or active infections, including tuberculosis and shingles. The medication should not be used in pregnant or breastfeeding women, or in patients with a history of an allergic reaction to Olumiant.
Overdose:
Currently, there is limited information on the specific symptoms that may occur with an Olumiant overdose. In case of an overdose, patients should seek medical attention immediately.
Adverse Reactions:
Common adverse reactions of Olumiant may include headache, nausea, and upper respiratory infections. Less common adverse reactions may include serious infections, blood clots, or changes in cholesterol and liver enzyme levels.
In conclusion, Olumiant (baricitinib) is a prescription medication used to treat adults with moderate to severe rheumatoid arthritis. It works by inhibiting the activity of Janus kinases and reducing inflammation in the affected joint(s). Olumiant should be taken orally once daily and comes in 2 mg and 4 mg tablets. Patients should avoid contact with others who are sick while taking the medication. Patients with liver disease or active infections, pregnant or breastfeeding women, or those with a history of an allergic reaction should not take Olumiant. Proper storage conditions should be maintained, and patients should seek medical attention in case of an overdose. Common adverse reactions may include headache, nausea, and upper respiratory infections.
Reviews
There are no reviews yet.